Neglected Tropical Diseases Diagnosis

Neglected Tropical Diseases Diagnosis

Global Neglected Tropical Diseases Diagnosis Market to Reach US$10.3 Billion by 2030

The global market for Neglected Tropical Diseases Diagnosis estimated at US$7.1 Billion in the year 2023, is expected to reach US$10.3 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2023-2030. Conventional Method, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$5.4 Billion by the end of the analysis period. Growth in the Molecular / Modern Method segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 8.0% CAGR

The Neglected Tropical Diseases Diagnosis market in the U.S. is estimated at US$1.9 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 4.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Neglected Tropical Diseases Diagnosis Market - Key Trends and Drivers Summarized

Why Is Neglected Tropical Diseases Diagnosis Crucial for Global Health?

Neglected Tropical Diseases (NTDs) encompass a range of infectious diseases that predominantly affect populations in low-income regions. Accurate diagnosis of NTDs is critical for controlling and eradicating these diseases, which include conditions like dengue, leishmaniasis, Chagas disease, and schistosomiasis. Early and precise diagnosis helps prevent complications, reduces transmission, and aids in effective treatment. Traditionally, diagnosing NTDs has been challenging due to limited resources, lack of infrastructure, and the need for specialized equipment. However, innovations in diagnostic technologies, such as rapid diagnostic tests (RDTs), molecular assays, and point-of-care devices, are transforming NTD diagnosis by making it faster, more accurate, and accessible in remote areas.

What Are the Key Segments in the NTD Diagnosis Market?

Diagnostic techniques include serological tests, molecular tests, and imaging-based diagnostics. Serological tests, which detect antibodies or antigens, are widely used for diseases like dengue and leishmaniasis, while molecular tests, such as polymerase chain reaction (PCR), are preferred for their accuracy in detecting diseases like Chagas and schistosomiasis. In terms of disease type, the market covers parasitic, viral, and bacterial NTDs, with parasitic NTDs being the largest segment due to their prevalence in affected regions. Major end-users of NTD diagnostics include hospitals, clinics, public health laboratories, and research institutions that are focused on improving disease surveillance and treatment strategies.

How Are Technological Innovations Enhancing NTD Diagnosis?

Technological advancements are at the forefront of improving NTD diagnosis. Rapid diagnostic tests (RDTs) have emerged as a cost-effective solution, offering results within minutes and facilitating quick decision-making in remote areas with limited healthcare infrastructure. Molecular diagnostics, such as real-time PCR and loop-mediated isothermal amplification (LAMP), offer high sensitivity and specificity, making them essential for accurate disease detection. Digital health tools, including mobile-based diagnostic kits and AI-powered diagnostic algorithms, are also being deployed to enhance disease detection, data collection, and reporting in NTD-affected regions. These technologies not only improve diagnosis but also contribute to global efforts toward NTD elimination.

What Factors Are Driving the Growth in the Neglected Tropical Diseases Diagnosis Market?

The growth in the Neglected Tropical Diseases Diagnosis market is driven by several factors, including the increasing burden of NTDs in low- and middle-income countries and the urgent need for accurate, affordable diagnostics. Government and non-governmental organizations` efforts to control and eliminate NTDs through better surveillance and diagnosis have significantly boosted the demand for innovative diagnostic tools. Technological advancements, such as portable diagnostic devices and point-of-care testing, have made NTD diagnosis more accessible, even in resource-constrained settings. Additionally, international funding from global health initiatives, such as the World Health Organization and the Bill & Melinda Gates Foundation, is promoting research and development in NTD diagnostics. The increasing focus on integrating diagnostics into primary healthcare systems is also driving market growth.

Select Competitors (Total 33 Featured) -

• Abbott Laboratories
• Beckman Coulter/Danaher
• Bio-Rad Laboratories, Inc.
• Coris Bioconcept SPRL
• DiaSys Diagnostic Systems GmbH
• F. Hoffmann-La Roche Ltd.
• Genome Diagnostics Pvt. Ltd
• InBios International, Inc.
• Life Technology
• Novartis Diagnostics., Ltd.
• Omega Diagnostics Group PLC
• Ortho-Clinical Diagnostics
• Oscar Medicare Pvt Ltd.
• Premier Medical Corporation Ltd.
• Siemens Healthcare
• Thermo Fisher Scientific, Inc.
• Wako Chemicals, Inc.
• ZeptoMetrix

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.